What are the key financial results for the quarter ended September 30, 2024?

The 8-K filing itself does not contain the specific financial figures. Investors should refer to Exhibit 99.1, the press release dated October 25, 2024, which accompanies this filing, for detailed information on revenue, profitability, and other key financial metrics for the quarter.

What is the impact of the skin health business reporting change on Colgate-Palmolive's overall financial performance?

The realignment of the skin health business reporting from the Europe segment to the North America segment, effective July 1, 2024, has no impact on Colgate-Palmolive's consolidated financial results, financial position, or cash flows. It is an internal organizational and reporting adjustment.

Why has Colgate-Palmolive recast its historical segment information?

The company has recast its historical segment information (Exhibit 99.2) to provide investors with data that is consistent with the new reporting structure for the skin health business. This allows for a more meaningful comparison of performance across periods under the updated segmentation.

Where can I find the detailed segment performance information for historical periods?

Exhibit 99.2 of this 8-K filing contains the recast segment information by operating segment for the years 2021, 2022, and 2023, as well as for various quarters up to June 30, 2024. This information should be read in conjunction with the company's previously filed 10-K and 10-Q reports.

CL 8-K SEC Disclosure — Oct 25, 2024

Summary

Colgate-Palmolive Company (CL) filed an 8-K on October 25, 2024, to announce its financial results for the quarter ended September 30, 2024. The core of the filing pertains to the earnings press release, which is incorporated by reference. While specific financial figures are not detailed within the 8-K text itself, investors should note that this filing serves as the official notification of these results, typically accompanied by detailed performance metrics, revenue, and profit figures discussed in the press release. Additionally, the company disclosed a change in its reporting structure for the skin health business, effective July 1, 2024. This change involves realigning the skin health business results from the Europe segment to the North America segment. Importantly, this realignment does not impact Colgate-Palmolive's consolidated financial results or position. The company has provided recast historical segment information to offer investors a consistent view under the new structure, which is included as an exhibit. Investors should consult the referenced press release (Exhibit 99.1) for the actual financial performance data and the recast segment information (Exhibit 99.2) for a clearer understanding of segment reporting going forward.

Key Highlights

1Colgate-Palmolive announced its Q3 2024 earnings results via press release on October 25, 2024, filed as an exhibit to this 8-K.
2A significant operational update includes the realignment of the skin health business reporting structure, effective July 1, 2024.
3The skin health business results will now be reported within the North America segment, previously part of the Europe segment.
4This reporting change is purely for organizational and disclosure purposes and has no impact on the company's consolidated financial results or position.
5Colgate-Palmolive has provided recast historical segment information to align with the new reporting structure, covering periods from 2021 through Q2 2024.
6Investors are directed to the earnings press release (Exhibit 99.1) for detailed financial performance data for the quarter ended September 30, 2024.
7The recast segment information (Exhibit 99.2) is intended to provide historical context under the updated reporting framework.

COLGATE PALMOLIVE CO 8-K Report, Corporate Update (Oct 25, 2024)

Summary

Key Highlights

Frequently Asked Questions